# Saci Nivo Rela for TNBC

Source: https://onco.cc/trials/nct06963905/  
OnCo record `nct06963905` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of nivolumab and sacituzumab govitecan in triple-negative breast cancer, run by Yale University, now recruiting.

## Summary

Saci Nivo Rela for TNBC is a phase 1/2, randomised interventional study registered as NCT06963905 by Yale University, with a registry enrolment figure of 60 participants, started 2025-12-29 and due to reach its primary completion in 2030-12. Interventions recorded: Relatlimab FDC + Nivolumab; Sacituzumab Govitecan (SG); Nivolumab. Conditions listed: Metastatic Triple-negative Breast Cancer. Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: SIMONE
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06963905
- Phase: 1/2
- Setting: Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for Patients With Metastatic Triple Negative Breast Cancer
- Sponsor: Yale University
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06963905: https://clinicaltrials.gov/study/NCT06963905

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Nivolumab](https://onco.cc/drugs/nivolumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06963905.json